Update your location to show providers, locations, and services closest to you.
Critical Care Medicine Specialist, Pulmonologist (Lung Specialist)
My name is Amir Emtiazjoo, MD, MSc, and I am an associate professor of medicine in the University of Florida Division of Pulmonary, Critical Care & Sleep Medicine, and the medical director of the Lung Transplant Program. My clinical work focuses on lung and heart-lung transplant as well as pulmonary critical care, specifically with interests in acute lung failure and extracorporeal critical care management.
I received my medical degree from Tehran University of Medical Sciences and completed my internal medicine residency at the University of California San Francisco. Then, I completed specialty fellowship training in pulmonary and critical care medicine at the Indiana University School of Medicine, and a fellowship in lung and heart-lung transplant at Stanford Medical Center. In addition, I earned a Master of Science degree in molecular biology from McGill University Division of Experimental Medicine.
I am actively involved in basic science and translational research in lung transplant immunology. I have investigated the role of humoral autoimmunity to collagen V in development of primary graft dysfunction in a pre-clinical model of lung transplantation and later in a multi-center human exploratory study. More recently, my research has been focused on lung allograft tolerance and using innate immune therapeutics to modulate early graft injury. In addition to modulation of innate immune mechanisms, I explored dendritic cell reprogramming in efforts to modulate all immunity.
The objective of the trial is to assess the long-term safety and efficacy of L-CsA plus Standard of Care (SoC) in the treatment of BOS in single (SLT) and double lung transplant (DLT) recipients.
The objective of the trial is to assess efficacy and safety of add-on aerosolized liposomal cyclosporine A (L-CsA) to Standard of Care (SoC) therapy as compared to SoC therapy alone in the treatment of Bronchiolitis obliterans syndrome (BOS) in…
The objective of the trial is to assess efficacy and safety of add-on aerosolized liposomal cyclosporine A (L-CsA) to Standard of Care (SoC) therapy as compared to SoC therapy alone in the treatment of Bronchiolitis obliterans syndrome (BOS) in…
Please note: Some physicians and practices might not accept a specific insurance plan. Our list is also subject to change, and sometimes that change is not yet reflected in this list. Please contact the practice to confirm that your insurance is accepted. A representative will be happy to assist you.